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Abstract
Background—Live oral rotavirus vaccines have been less immunogenic and efficacious for 
children of developing countries than for those in middle income and industrialized countries, and 
the basis for these differences is not fully understood. Recently, we demonstrated that breastmilk 
from mothers in India had significantly higher IgA and neutralizing activity against rotavirus that 
could reduce the effective titer of rotavirus vaccines reaching the gut when compared with that 
from mothers in the United States. We extended our study to understand the specific contribution 
of those nonanti-body components in breastmilk to the neutralizing activity against rotavirus 
vaccine we observed.
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Methods—Breastmilk samples were collected from mothers of breastfeeding infants aged 
between 4 and 29 weeks (ie, vaccine eligible age) in India (N = 40), South Africa (N = 50) and the 
United States (N = 51). We examined breastmilk for lactoferrin, lactadherin, rotavirus-specific 
IgA and neutralizing activity against 3 rotavirus vaccine strains (Rotarix, RotaTeq G1 and 116E) 
using enzyme immunoassays, a plaque reduction assay or a microneutralization assay.
Results—We observed higher levels of lactoferrin, lactadherin, IgA and neutralizing activity in 
breastmilk specimens from Indian and South African women than those from American women. 
We demonstrated positive associations between levels of lactoferrin or IgA and neutralizing 
activity in Indian and South African specimens, but not in American specimens. We demonstrated 
that the inhibitory effect of lactoferrin was dose- or species-dependent, as evidenced by greater 
reduction in titer of Rotarix and 116E by human lactoferrin. Lactadherin also exhibited inhibitory 
activity to rotavirus vaccines but appeared to be less effective.
Conclusions—The lower immunogenicity and efficacy of rotavirus vaccines in developing 
countries could be explained, in part, by synergistic inhibitory effect of high levels of antibody and 
nonantibody components in breastmilk consumed by infants at the time of immunization. 
Therefore, there is a need for alternative rotavirus vaccine strategies in breast-feeding populations.
Keywords
rotavirus; breastmilk; lactoferrin; lactadherin; vaccine
Rotavirus is the most common cause of severe diarrhea in children less than 5 years of age. 
Rotavirus infection causes an estimated 453,000 deaths per year worldwide, with more than 
85% of these deaths occurring in resource-limited countries.1 In 2006 and 2009, World 
Health Organization recommended use of the 2 licensed vaccines, a monovalent attenuated 
human rotavirus vaccine (Rotarix) and a pentavalent bovine-human rotavirus reassortant 
vaccine (RotaTeq). Both vaccines showed high efficacy (85%–98%) against severe diarrhea 
and hospitalization from rotavirus among young children in developed and middle income 
countries.2–4 However, the same vaccines were less immunogenic and have shown modest 
efficacy ranging from 18% to 64% in resource-limited countries of Africa, Asia and Latin 
America.5–10
The mechanisms underlying the lower immunogenicity and efficacy of live oral rotavirus 
vaccines in developing countries remain poorly understood but are likely to be 
multifactorial, including the inhibitory effects of immune factors in breastmilk at the time of 
immunization.11,12 However, results from clinical trials of early candidate and recently 
licensed vaccines have been controversial. Early studies reported that breast-feeding 
appeared to reduce serococonversion rates among American and Finnish infants who 
received RIT 4237 bovine rotavirus vaccine or rhesus rotavirus vaccine (RRV).13–15 
Subsequent studies showed similar responses and protection in breastfed and nonbreastfed 
US infants who received rhesus rotavirus reassortant vaccine (RotaShield) or pentavalent 
vaccine RotaTeq.16,17 However, a recent study has demonstrated a small reduction in 
immunogenicity and efficacy of Rotarix in breastfed European infants compared with those 
who exclusively formula-fed.18 Effects of breastmilk and breast-feeding on efficacy of 
rotavirus vaccines in infants of the developing world have not been evaluated.
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We recently reported significantly higher IgA titer and neutralizing activity and greater 
inhibitory effect on rotavirus vaccines in breastmilk from women in India than those in the 
United States.19 In the present study, we extended our study to examine profiles of both 
rotavirus-specific IgA and nonspecific innate immune factors in breastmilk from mothers of 
developed and resource-limited countries and investigate their possible associations with 
neutralizing activity in breastmilk. Innate immune factors such as lactoferrin, lactadherin, 
mucin and butyrophilin in breastmilk have previously shown to inhibit the replication of 
animal and human rotaviruses in intestinal epithelial cells.20,21 These factors have also been 
reported to mediate protection against symptomatic infection in infants.22,23 To date, we 
know of no studies that have specifically evaluated both IgA and innate immune factors in 
breastmilk as inhibitors of rotavirus vaccine replication and response.
MATERIALS AND METHODS
Subjects and Specimen Collection
From January 2007 to October 2008, we collected 5 to 10 mL of breastmilk from mothers in 
India and the United States who were breast-feeding their infants of 4 to 29 weeks, 
approximately the recommended age for the administration of rotavirus vaccine. South 
African samples were collected during the period May 2002 to March 2005 from mothers 
who were breast-feeding similar aged infants. Each specimen was assigned a unique 
identifier to maintain the anonymity of the donor and data on the ages of the mother and 
infant and the date of collection were recorded. All specimens were kept frozen at –70°C 
before being shipped and analyzed in the laboratory at the US Centers for Disease Control 
and Prevention. Informed consent was obtained from all participants. The protocols were 
reviewed and approved by the institutional review boards of each of the participating 
institutions. This research did not require review by the Centers for Disease Control and 
Prevention institutional review board because the Centers for Disease Control and 
Prevention tested preexisting, anonymous specimens.
Detection of Rotavirus-specific Antibody in Breastmilk
Rotavirus-specific IgA in breastmilk samples was determined by enzyme-linked 
immunosorbent assay as previously described.24,25 Briefly, microplate wells were coated 
with rabbit hyperimmune serum to rhesus rotavirus (RRV) and incubated with diluted RRV 
or blotto (5% skim milk in phosphate-buffered saline [PBS]); after washing, breastmilk 
samples that were serially diluted from 1:2 to 1:2048 in diluent buffer (PBS supplemented 
with 1% skim milk and 0.5 % [v/v] of 10% polyoxyethylene ether W1) were added to the 
wells, followed by horseradish peroxidase–conjugated goat antihuman IgA antibodies 
(Sigma). After incubation and washing, the reactions were developed with tetramethyl 
enzidine (Sigma, St. Louis, MO) and stopped with 1N HCl. Optical density (OD) was 
determined at 450 nm with an enzyme immunoassay reader (MRX Revelation, Dynex 
Technologies, Chantilly, VA). IgA titers in breastmilk were calculated as the reciprocal of 
the highest dilution that gave a mean OD greater than the cutoff value (3 standard deviations 
above the mean OD of the blotto wells).
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Measurement of Nonantibody Components in Breastmilk
Lactoferrin concentrations in breastmilk specimens were determined with an enzyme-linked 
immunosorbent assay kit specific for human lactoferrin (Kamiya Biomedical Co., Seattle, 
WA). Samples were diluted 1:50,000 with diluent buffer, and lactoferrin concentrations 
were measured using standard curves (range: 0–100 ng/mL) according to manufacturer’s 
instructions. Lactadherin concentrations in breastmilk were determined from standard curves 
(range: 0–50 µg/mL) using a commercial enzyme-linked immunosorbent assay kit (Cusabio 
Biotech Co., China).
Measurement of Neutralizing Activity in Breastmilk
Overall rotavirus-specific neutralizing activity in breast-milk was measured by a 
microneutralization assay as previously described.24 Briefly, breastmilk samples (50 µL) in 
2-fold dilutions were mixed with an equal volume of trypsin-activated vaccine virus 
(Rotarix, RotaTeq G1 [WC3 × WI79] or 116E) in 96-well plates to yield a concentration of 
4000 fluorescence focus unit per well and incubated at 37°C for 1 hour. Monolayers of 
MA104 cells grown in 96-well plates were washed with PBS and incubated with 100 µL of 
diluted breastmilk and virus mixture. After incubation at 37°C for 1 hour, the plates were 
washed with PBS and incubated with 100 µL of Iscove’s Modified Dulbecco’s Medium 
containing 5 µg/ mL trypsin (Gibco, Grand Island, NY). After 20 hours incubation at 37°C, 
the plates were fixed with 15 µL of 37% formaldehyde at 4°C for 30 minutes. Rotavirus 
antigen in MA104 cells was detected by incubating plates with a rabbit anti-RRV 
hyperimmune serum, horseradish peroxidase–labeled antirabbit IgG (KPL, Gaithersburg, 
MD) and then tetramethyl enzidine. Neutralizing titer in a breast-milk specimen was 
determined as the reciprocal of the highest dilution that showed a greater than 70% 
reduction in the absorbance value compared with that in virus-only controls.
Neutralizing activity against rotavirus vaccine strains by lactoferrin and lactadherin was 
assessed in cell culture by a plaque reduction assay or a microneutralization assay. Human 
lactoferrin and bovine lactoferrin (both from Sigma) were dissolved in H2O (1 mg/mL), and 
human lactadherin (R&D systems, Inc., Minneapolis, MN) was reconstituted in PBS (200 
µg/mL). Approximately 100 plaque forming units of trypsin-activated vaccine virus 
(Rotarix, RotaTeq G1 or 116E) in 100 µL of culture medium was incubated with an equal 
volume of serially diluted lactoferrin and lactadherin (100, 50, 25, 12.5 and 6.25 µg) for 1 
hour at 37°C. The mixtures were placed on monolayers of MA104 cells in 6-well plates and 
after 1 hour incubation, the wells were overlaid with 0.3% ME agarose (Lonza, Rockland, 
ME) in Iscove’s Modified Dulbecco’s Medium (Gibco) containing 5 µg/mL of trypsin. The 
plates were then stained with 2% neutral red (Sigma), and rotavirus plaques in triplicate 
wells were counted. The percent reduction in virus titer was calculated by comparing the 
numbers of plaques in wells of virus-lactoferrin or virus-lactadherin mixtures to those of 
virus-only controls. For microneutralization assay, lactoferrin (50 µL) and lactadherin (50 
µL) in 2-fold dilutions (100, 50, 25, 12.5, 6.25, 3.13, 1.6, 0.78, 0.39 and 0.19 µg/well) were 
mixed with an equal volume of trypsin-activated vaccine virus (Rotarix, RotaTeq G1 or 
116E) to yield a concentration of 4000 fluorescence focus unit per well and incubated at 
37°C for 1 hour. Monolayers of MA104 cells grown in 96-well plates were washed with 
PBS and incubated with diluted lactoferrin- or lactadherin-virus mixture. After incubation at 
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37°C for 1 hour, the plates were washed with PBS and incubated with 100 µL of Iscove’s 
Modified Dulbecco’s Medium (Gibco) containing 5 µg/mL trypsin. After 20 hours 
incubation at 37°C, the plates were fixed with 15 µL of 37% formaldehyde at 4°C for 30 
minutes. Rotavirus antigen in MA104 cells was detected by incubating plates with a rabbit 
anti-RRV hyperimmune serum, horseradish peroxidase–labeled antirabbit IgG and 
tetramethyl enzidine and then stopped with 1N HCl. OD was determined at 450 nm with an 
enzyme immunoassay reader. Inhibitory effect of lactoferrin and lactadherin on rotavirus 
vaccine strains was determined as the reduction in absorbance value in treated samples 
compared with that in virus-only controls.
Statistical Analysis
The Kruskal–Wallis test was used to analyze the differences in concentration of nonantibody 
components among breastmilk specimens from mothers in different countries. The 
Kolmogorov– Smirnov goodness-of-fit test was used to compare the distributions of 
antibody titers in breastmilk specimens from each country. Univariate and multivariable 
linear regression analyses were performed to examine the relationships between neutralizing 
activity and titer of IgA or concentration of lactoferrin or lactadherin in breastmilk 
specimens. Log transformed (log2) titers of neutralizing activity and IgA were used in the 
regression models. Regression models were assessed for violations of assumptions. When 
the assumptions of the regression model were not met, Spearman rank correlations were 
used in univariate analyses and multivariate analyses were not performed. A P < 0.05 was 
considered statistically significant. The calculations were performed with the PASW 
Statistics 18.0 (IBM, Chicago, IL).
RESULTS
A total of 141 breastmilk specimens were collected from mothers with infants of 4 to 29 
weeks of age in India (n = 40), South Africa (n = 50) and the United States (n = 51). The age 
of American and South African women ranged from 16 to 41 years (median age of 35; 
range: 16–41 years) versus (median age of 22; range: 16–40 years), respectively. The age 
information of Indian women was not available. The age of infants from 3 countries ranged 
from 1.0 to 6.6 months, with a median of 1.5 (range: 1–1.8 months), 2.8 (range: 1.4–6.6 
months) and 3.1 (range: 1.2–5.7 months) for South Africa, United States and India, 
respectively.
We extended our previous study by examining breastmilk specimens from South African 
mothers for rotavirus-specific IgA and overall neutralizing activity against 3 rotavirus 
vaccine strains, Rotarix, RotaTeq G1 and 116E (Fig. 1). Cumulative frequency of IgA titers 
in breastmilk specimens from South African women fell between those from Indian and 
American women but was more similar to that of Indian specimens (P = 0.07). IgA titers in 
Indian and South African samples were as much as 4-fold higher than those from American 
mothers (P < 0.05). Breastmilk showed gradient cumulative frequencies in neutralizing 
activity to all 3 vaccine strains, with the highest, intermediate and lowest titers seen in 
specimens from India, South Africa and the United States, respectively.
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We measured the concentrations of lactoferrin and lactadherin in breastmilk from women in 
India, South Africa and the United States (Fig. 2). The median concentration of lactoferrin in 
specimens from Indian, South African and American women was 1.85 mg/mL (range: 0.56–
5.52 mg/mL), 2.2 mg/mL (range: 0.82–6.23 mg/mL) and 1.45 mg/mL (range: 0.42–2.67 mg/
mL), respectively. The median concentration of lactadherin in specimens from Indian, South 
African and American mothers was 0.22 mg/ mL (range: 0.06–0.66 mg/mL), 0.02 mg/mL 
(range: 0–0.33 mg/ mL) and 0.002 mg/mL (range: 0–0.073 mg/mL), respectively. The levels 
of both lactoferrin and lactadherin in breastmilk of both Indian and South African women 
were significantly higher than those from women in the United States (P < 0.005). The 
concentrations of lactoferrin in breastmilk specimens from South African women were not 
significantly different from those of Indian women (P = 0.79), whereas the concentrations of 
lactadherin in breastmilk specimens from South African mothers were significantly lower 
than those from Indian mothers (P < 0.001).
We then analyzed possible associations between the concentrations of lactoferrin or 
lactadherin and the levels of neutralizing activity in breastmilk against rotavirus vaccine 
strains (Fig. 3). In univariate analyses, concentrations of lactoferrin in breastmilk from 
Indian mothers were significantly associated with neutralizing activity against Rotarix (r = 
0.71, df = 38, P < 0.001), RotaTeq G1 (r = 0.60, df = 38, P < 0.001) and 116E (r = 0.37, df= 
38, P = 0.018). Similarly, the concentrations of lactoferrin in specimens from South African 
women had a weak but significant association with neutralizing activity against Rotarix (r = 
0.40, df = 48, P = 0.004), RotaTeq G1 (r = 0.34, df = 48, P = 0.016) and 116E (r = 0.59, df = 
48, P < 0.001) in univariate analyses. By contrast, no associations were observed between 
the levels of lactoferrin and neutralizing activity against the 3 vaccine strains in breastmilk 
from American mothers. Additionally, no significant associations were observed between 
the concentrations of lactadherin in breastmilk from India, South Africa and the United 
States and neutralizing activity against Rotarix and RotaTeq G1 (results not shown).
We further observed significant associations between the titers of rotavirus-specific IgA in 
specimens from Indian women and neutralizing activity against the 3 vaccine strains 
(Rotarix: r = 0.84, df = 38, P < 0.001; RotaTeq G1: r = 0.59, df = 38, P < 0.001; 116E: r = 
0.40, df = 38, P = 0.011) in univariate analyses (Fig. 4). Similar associations were also 
observed in univariate analyses between IgA titers and neutralizing activity against Rotarix 
(r = 0.63, df = 48, P < 0.001) and 116E (r = 0.43, df = 48, P = 0.002) but not RotaTeq G1 (r 
= 0.09, df = 48, P = 0.532) in South African samples. No such associations were seen in 
specimens from American women.
In multivariable regression analyses, the IgA titer in Indian women was significantly 
correlated with neutralizing activity against Rotarix (partial R = 0.67, df = 36, P < 0.001) but 
not RotaTeq G1 (partial R = 0.25, df = 36, P = 0.22) or 116E (partial R = 0.14, df = 36, P = 
0.41) when the concentrations of lactoferrin and lactadherin were held constant. The 
concentrations of lactoferrin and lactadherin were not correlated with neutralizing activity 
against any of the 3 vaccine strains in Indian women in the multivariate regression model. 
IgA titers and concentrations of lactoferrin were highly correlated (r = 0.72, df = 38, P < 
0.001) in Indian women. Among women in South Africa, the IgA titer was significantly 
correlated with the neutralizing activity against Rotarix (partial R = 0.56, df = 46, P < 0.001) 
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and 116E (partial R = 0.29, df = 46, P = 0.04) and not correlated with neutralizing activity 
against RotaTeq (partial R = 0.02, df = 46, P = 0.88) in multivariable regression analyses 
when the concentrations of lactoferrin and lactadherin were held constant. The concentration 
of lactoferrin was correlated with neutralizing activity against 116E (partial R = 0.48, df = 
46, P < 0.001) and RotaTeq G1 (partial R = 0.29, df = 46, P = 0.04) but not Rotarix (partial 
R = 0.27, df = 46, P = 0.07) in South African women in the multivariate regression model. 
The concentration of lactadherin was not predictive of neutralizing activity against any of 
the 3 vaccine strains in South African women in the multivariate regression model. In South 
African women, IgA titers and concentrations of lactoferrin were weakly correlated (r = 
0.28, df = 48, P = 0.05).
Lastly, we examined whether human lactoferrin and lactadherin could reduce the titer of 
rotavirus vaccine strains in MA104 cells by using a plaque reduction assay (Fig. 5). The 
replication of Rotarix and 116E was inhibited by human lactoferrin in a dose-dependent 
manner. For example, 100 µg of human lactoferrin reduced the titer of Rotarix by 60% and 
that of 116E by 55%. By contrast, human lactoferrin appeared to have little effect on 
RotaTeq G1. To test if inhibitory effect of lactoferrin on rotavirus is species-specific, we 
performed the same assay using bovine lactoferrin. Bovine lactoferrin showed inhibitory 
activity against RotaTeq G1, but appeared to be less effective against Rotarix and 116E. 
Human lactadherin reduced titers of all 3 vaccine strains in a dose-dependent manner. 
Bovine lactadherin was not available for testing.
We also examined neutralizing activity of human lactoferrin and lactadherin against the 3 
vaccine strains by a microneutralization assay (Fig. 6). Both human lactoferrin and 
lactadherin reduced the infectivity of Rotarix, RotaTeq G1 and 116E in a dose-dependent 
manner. However, lactoferrin appeared to be slightly more efficient. Bovine lactoferrin also 
showed inhibitory effect on the infectivity of all 3 vaccine strains, indicating a lack of 
apparent species-specific neutralizing activity by this method.
DISCUSSION
Both antibody and innate immune factors and their neutralizing activity in breastmilk have 
been shown to inhibit rotavirus replication in vitro and are believed to play a role in the 
protection against rotavirus gastroenteritis in children.11,22,23 In our previous study, we 
demonstrated significantly higher titers of rotavirus-specific IgA and neutralizing activity in 
breastmilk specimens from mothers in India than those from American women.19 That study 
suggested that higher levels of antibody in breastmilk may have greater reduction in the 
potency, immunogenicity and efficacy of live oral rotavirus vaccines among infants in 
resource-limited countries at the very time of vaccine administration. Similarly in this study, 
we demonstrated significantly higher levels of lactoferrin and lactadherin in breastmilk 
specimens from mothers in India and South Africa than those from the United States. We 
further observed significant associations between concentrations of lactoferrin and levels of 
IgA in breastmilk from Indian mothers. In multivariate regression analyses, levels of IgA 
were significantly correlated with titers of neutralizing activity against Rotarix strain in 
specimens from India and against Rotarix and 116E strains in specimens from South Africa. 
The concentration of lactoferrin was only correlated with neutralizing activity against 116E 
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and RotaTeq G1 strains in specimens from South Africa, and the concentration of 
lactadherin was not predictive of neutralizing activity against any of the vaccine strains in 
any of the settings. Our findings show that both IgA and lactoferrin contribute to 
neutralizing activity against rotavirus in breastmilk of mothers in some developing country 
settings.
Lactoferrin exhibited inhibitory activity against rotavirus vaccine strains in vitro in a dose-
dependent manner. This neutralization and reduction in titer appeared to be assay and 
species-dependent. By a plaque reduction assay, we found human lactoferrin inhibited the 
replication of the 2 human vaccine strains Rotarix and 116E and bovine lactoferrin reduced 
the titer of a reassortant bovine vaccine strain containing a gene encoding human rotavirus 
VP7. Our results were in agreement with a previous report where human lactoferrin and 
lactadherin showed significant dose-dependent inhibition against Wa strain, whereas bovine 
lactoferrin had no significant effect on Wa.21 On the other hand, we observed similar 
inhibition against vaccine strains with human or bovine lactoferrin by using a 
microneutralization assay.
The mechanisms of antirotavirus activities by lactoferrin and lactadherrin are complicated 
and remain poorly defined. Data from plaque reduction assays, which usually measure early 
events in virus–cell interactions, suggest that lactoferrin could bind to the very same viral 
receptor (eg, integrins) on the surface of cells in a species-specific manner and repel virus or 
interfere with virus–cell interactions and thus hinder its subsequent cell penetration. In 
addition, lactoferrin could inhibit rotavirus infection by directly binding to viral particles.26 
Our findings of broad inhibition of human and bovine vaccine strains by human or bovine 
lactoferrin using a microneutralization assay that measures multiple steps of virus–cell 
interactions support a notion of indirect antiviral activities by nonantibody components after 
virus enters the cell. For example, lactoferrin and lactadherin could induce the activation of 
nature killer cells, macrophages or dendritic cells in the gut,27 thereby mobilizing and 
alerting the adaptive immune system to produce rotavirus-specific antibodies. Studies are 
needed to compare and substantiate this potential antirotavirus mechanism in children from 
low, middle and high income countries.
To our knowledge, this is the first study to report gradient concentrations of nonantibody 
components in breastmilk of mothers in developing versus developed countries. The 
findings suggest that innate immune factors, together with antibodies, could act 
independently or work synergistically to suppress the replication of oral rotavirus vaccines 
and in part explain the lower immunogenicity and efficacy of the currently licensed Rotarix 
and RotaTeq and early candidate vaccines among children in resource-limited countries of 
Africa, Asia and Latin America.6,9,10,28 These findings could have implications for the 
development of new rotavirus vaccines and ongoing immunization programs using licensed 
vaccines. For example, recent clinical trials of 116E, a live oral rotavirus vaccine derived 
from neonatal strain, demonstrated a high seroconversion (89.7%) among vaccinated infants 
in India.29 This robust immune response may be due to a 30-minute delay of breast-feeding 
before and after immunization, thus likely reducing neutralizing activity on the vaccine by 
antibody and nonantibody components in breast-milk.29 Additionally, the presence of 
bovine rotavirus VP4 in the 116E vaccine may also resist the suppressive effect by immune 
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factors in breastmilk.30 Studies are in progress to assess whether a transient delay of breast-
feeding before or after vaccine administration could improve immune response and 
protective efficacy of Rotarix in several developing countries.
Some limitations should be considered in interpreting our data. First, we only examined 
nonantibody components and IgA in breastmilk from mothers in a few countries; more 
specimens from other resource-limited African, Asian and Latin American countries should 
be examined to fully assess differential profiles and potential impact on the performance of 
live oral rotavirus vaccines in different settings. Second, although high levels of antibody 
and associated neutralizing activity in breastmilk of mothers in resource-limited countries 
are believed to result from frequent exposures to rotavirus, we need to establish whether 
such associations can be extrapolated to innate immune factors such as lactoferrin and 
lactadherin. Further studies are needed to investigate the effects of rotavirus infection or 
exposure and environmental conditions on the innate immune factors among mothers and 
children in resource-limited countries. Third, lactoferrin or lactadherin and antibody are 
critical components of innate and adaptive immunity and are known to play an important 
role in protection against bacterial and viral infections. Although our study shows inhibitory 
effect of breastmilk on rotavirus vaccines, it is essential that in resource-limited settings, this 
finding does not fuel a perception that breast-feeding may be harmful. In such settings, it is 
important to promote exclusive breast-feeding for the first 6 months of the infant’s life as an 
important infant survival strategy.31 Lastly, to avoid this potential inhibitory effect of breast-
feeding on the response to live rotavirus vaccine, it is important that alternative approaches 
to oral vaccination, such as inactivated vaccines, need to be accelerated as an insurance 
policy for global immunization against rotavirus.28
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Cumulative frequency profiles of rotavirus-specific antibodies in breastmilk specimens from 
mothers in India (IN), South Africa (SA) and the United States (US). Milk specimens were 
tested for IgA (A) and neutralizing activity (NA) against vaccine strains Rotarix (B), 
RotaTeq G1 (C) and 116E (D) as described in the text.
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Box plots (median, quartiles) of the concentration quartiles of lactoferrin (A) and lactadherin 
(B) in breastmilk from mothers in India (IN), South Africa (SA) and the United States (US). 
Milk specimens were tested for lactoferrin and lactadherin as described in the text.
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Regression analyses of relationships between the concentrations of lactoferrin and 
neutralizing activity against 3 vaccine strains in breastmilk from mothers in India (IN), 
South Africa (SA) and the United States (US). The analyses were done as described in the 
text. The linear regression assumptions were not satisfied for the samples from the US, so 
Spearman rank correlation was used to examine the relationship between the concentrations 
of lactoferrin and neutralizing activity against 3 vaccine strains in breastmilk from American 
mothers.
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Regression analyses of relationships between rotavirus-specific IgA titer and neutralizing 
activity against 3 vaccine strains in breastmilk from mothers in India (IN), South Africa 
(SA) and the United States (US). The analyses were done as described in the text. The linear 
regression assumptions were not satisfied for the samples from the US, so Spearman rank 
correlation was used to examine the relationship between rotavirus-specific IgA titer and 
neutralizing activity against 3 vaccine strains in breastmilk from American mothers.
Moon et al. Page 15














Inhibitory effect of lactoferrin and lactadherin on rotavirus vaccine strains: species-specific 
activity by a plaque reduction assay. Human lactoferrin (A), bovine lactoferrin (B) and 
human lactadherin (C) were assayed and analyzed as described in the text.
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Inhibitory effect of lactoferrin and lactadherin on rotavirus vaccine strains: no apparent 
species-specific activity by a microneutralization assay. Human lactoferrin (A), bovine 
lactoferrin (B) and human lactadherin (C) were assayed and analyzed as described in the 
text.
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